Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals Misses on Revenue, Stock Up 2.39%

Corvus Pharmaceuticals reported a narrower-than-expected loss per share, which resulted in a positive stock reaction, with shares rising by 2.39%. However, the lack of revenue data and management commentary leaves investors without a clear view of the company's current performance and future direction. The stock's increase may reflect investor optimism despite the missing revenue figures.